Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182684 | 0.97 | — | — | |
| SCHEMBL6711921 | 0.86 | — | — | |
| SCHEMBL7440404 | 0.85 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1CEL | |
| SCHEMBL8838698 | 0.83 | CYP1A2 (0.54) | CYP1A2SIGMAR1MAPTEPHX1CEL | |
| SCHEMBL11651890 | 0.82 | CYP1A2 (0.52) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL9670510 | 0.81 | SIGMAR1 (0.54) | CYP1A2SIGMAR1MAPTEPHX1 | |
| SCHEMBL8417237 | 0.75 | CYP1A2 (0.39) | CYP1A2MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL8415898 | 0.75 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL8417235 | 0.75 | CYP1A2 (0.39) | CYP1A2MEN1ALDH1A1LMNAMAPT | |
| SCHEMBL8106998 | 0.74 | CYP1A2 (0.42) | CYP1A2SIGMAR1HPGDKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4647432-A1 | AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER, AND ORGANIC THIN FILM TRANSISTOR | Tosoh Corporation (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024162378-A1 | AROMATIC COMPOUND, ORGANIC SEMICONDUCTOR LAYER, AND ORGANIC THIN FILM TRANSISTOR | 東ソー株式会社 | 2024-08-08 | — | — | WO | disclosed |
| CN-107531693-B | 5 or 8-substituted imidazo [1, 5-a ] pyridines as indoleamine, tryptophan dioxygenase inhibitors | 百济神州有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3280715-B1 | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO [1, 5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES | BEIGENE LTD (KY) | 2020-11-25 | — | — | EP | disclosed |
| WO-2020193649-A1 | NEW THERAPEUTIC APPLICATION OF 1,2-DIOXOLANE-3,5-DISUBSTITUTED COMPOUNDS, AND METHOD FOR THE PRODUCTION THEREOF | Universite Paris-Saclay (FR) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020193650-A1 | PROCESS FOR PREPARING 1,2-ENDOPEROXIDE COMPOUNDS | Universite Paris-Saclay (FR) | 2020-10-01 | — | — | WO | disclosed |
| US-10647714-B2 | 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2020-05-12 | — | — | US | disclosed |
| CN-110872289-A | Novel 8-substituted imidazo [1,5-a ] pyridines as IDO1 and/or TDO inhibitors | 百济神州(北京)生物科技有限公司 | 2020-03-10 | — | — | CN | disclosed |
| US-20190284184-A1 | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10280163-B2 | 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases | BEIGENE, LTD. (KY) | 2019-05-07 | — | — | US | disclosed |
| US-5641765-A | TREATS PROSTATIC ADENOCARCINOMA, BENIGN PROSTATE HYPERTROPHY; ANTAGONSIT, ANTAGONISM | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| US-5618806-A | STEROID 5ALPHA-REDUCTASE INHIBITOR; USEFUL FOR TREATING BENIGN PROSTATIC HYPERTROPHY, BALDNESS, ACNE, VULGURIS, SEBORRHEA, FEMALE HIRSUTISM, AND PROSTATIC ADENOCARCINOMA | SMITHKLINE BEECHAM CORPORATION | 1997-04-08 | — | — | US | disclosed |
| EP-0669932-A4 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE. | SMITHKLINE BEECHAM CORP (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0638090-A4 | 17-g(a) AND 17-g(b)-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-CARBOXYLIC ACID. | SMITHKLINE BEECHAM CORP (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0669932-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0638090-A1 | 17$g(a) AND 17$g(b)-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1993022333-A1 | 17α AND 17β-SUBSTITUTED ESTRA-1,3,5(10)-TRIENE-3-CARBOXYLIC ACID | SMITHKLINE BEECHAM CORPORATION (US) | 1993-11-11 | — | — | WO | disclosed |
| US-4652551-A | PEPTIDE, HYPOTENSIVE | ABBOTT LABORATORIES (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0172346-A2 | Renin inhibiting compounds | ABBOTT LABORATORIES (US) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280163-B2 | 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases | IDO1, TPH1, IDO2 | CYP1A2 66/4885SIGMAR1 2570/4885HPGD 113/4885 |
| US-10647714-B2 | 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases | IDO1, TPH1, IDO2 | CYP1A2 66/4885SIGMAR1 2570/4885HPGD 113/4885 |
| US-20190284184-A1 | NOVEL 5 OR 8-SUBSTITUTED IMIDAZO[1,5-a]PYRIDINES AS INDOLEAMINE AND/OR TRYPTOPHANE 2,3-DIOXYGENASES | IDO1, TPH1, IDO2 | CYP1A2 72/4885SIGMAR1 2396/4885HPGD 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.